社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
LZH97
IP属地:未知
+关注
帖子 · 25
帖子 · 25
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
LZH97
LZH97
·
2021-11-07
EV to the mooooon
非常抱歉,此主贴已删除
看
2,608
回复
评论
点赞
7
编组 21备份 2
分享
举报
LZH97
LZH97
·
2021-10-21
To the moooo
Tesla Q3 Earnings in 6 Must-See Metrics<blockquote>特斯拉第三季度收益的6个必看指标</blockquote>
Expectations were high going into Tesla's(NASDAQ:TSLA) third-quarter earnings release -- and the com
Tesla Q3 Earnings in 6 Must-See Metrics<blockquote>特斯拉第三季度收益的6个必看指标</blockquote>
看
1,748
回复
2
点赞
9
编组 21备份 2
分享
举报
LZH97
LZH97
·
2021-10-07
Nice
非常抱歉,此主贴已删除
看
2,762
回复
评论
点赞
4
编组 21备份 2
分享
举报
LZH97
LZH97
·
2021-10-01
Nice
非常抱歉,此主贴已删除
看
1,297
回复
评论
点赞
3
编组 21备份 2
分享
举报
LZH97
LZH97
·
2021-09-24
Buy
IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.<blockquote>IPO开盘提醒:Cue Health开盘价为19.2美元,较IPO价格上涨20%。</blockquote>
(Sept 24) Cue Health Inc. opens for trading at $19.2, up 20% from IPO price. Company & Technology S
IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.<blockquote>IPO开盘提醒:Cue Health开盘价为19.2美元,较IPO价格上涨20%。</blockquote>
看
2,751
回复
2
点赞
8
编组 21备份 2
分享
举报
LZH97
LZH97
·
2021-09-15
Buy!
U.S. stocks close lower on worries over recovery, corporate tax hikes<blockquote>美国股市因对复苏和企业增税的担忧而收低</blockquote>
NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing
U.S. stocks close lower on worries over recovery, corporate tax hikes<blockquote>美国股市因对复苏和企业增税的担忧而收低</blockquote>
看
2,165
回复
1
点赞
8
编组 21备份 2
分享
举报
LZH97
LZH97
·
2021-09-06
Nice
非常抱歉,此主贴已删除
看
3,181
回复
2
点赞
8
编组 21备份 2
分享
举报
LZH97
LZH97
·
2021-09-04
Like and shareeee
非常抱歉,此主贴已删除
看
2,531
回复
评论
点赞
4
编组 21备份 2
分享
举报
LZH97
LZH97
·
2021-08-13
Liked and sharee
非常抱歉,此主贴已删除
看
1,461
回复
2
点赞
6
编组 21备份 2
分享
举报
LZH97
LZH97
·
2021-08-08
Like and share
非常抱歉,此主贴已删除
看
1,551
回复
3
点赞
10
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3581248713273658","uuid":"3581248713273658","gmtCreate":1618155327333,"gmtModify":1623759071275,"name":"LZH97","pinyin":"lzh97","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/0a48491665331819a9d1857c6b60743e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":3,"tweetSize":25,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.02","exceedPercentage":"80.75%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":845194577,"gmtCreate":1636297964094,"gmtModify":1636297964480,"author":{"id":"3581248713273658","authorId":"3581248713273658","name":"LZH97","avatar":"https://static.tigerbbs.com/0a48491665331819a9d1857c6b60743e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581248713273658","authorIdStr":"3581248713273658"},"themes":[],"htmlText":"EV to the mooooon","listText":"EV to the mooooon","text":"EV to the mooooon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845194577","repostId":"2181074782","repostType":4,"isVote":1,"tweetType":1,"viewCount":2608,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853282644,"gmtCreate":1634814817895,"gmtModify":1634814818033,"author":{"id":"3581248713273658","authorId":"3581248713273658","name":"LZH97","avatar":"https://static.tigerbbs.com/0a48491665331819a9d1857c6b60743e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581248713273658","authorIdStr":"3581248713273658"},"themes":[],"htmlText":"To the moooo ","listText":"To the moooo ","text":"To the moooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/853282644","repostId":"1119920564","repostType":4,"repost":{"id":"1119920564","kind":"news","pubTimestamp":1634814610,"share":"https://www.laohu8.com/m/news/1119920564?lang=zh_CN&edition=full","pubTime":"2021-10-21 19:10","market":"us","language":"en","title":"Tesla Q3 Earnings in 6 Must-See Metrics<blockquote>特斯拉第三季度收益的6个必看指标</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1119920564","media":"Motley Fool","summary":"Expectations were high going into Tesla's(NASDAQ:TSLA) third-quarter earnings release -- and the com","content":"<p>Expectations were high going into <b>Tesla</b>'s(NASDAQ:TSLA) third-quarter earnings release -- and the company didn't disappoint. Revenue and earnings per share both came in above analysts' average forecasts, setting records for the company.</p><p><blockquote>期望值很高<b>特斯拉</b>(纳斯达克:TSLA)发布了第三季度财报,该公司没有让人失望。营收和每股收益均高于分析师平均预期,创下该公司纪录。</blockquote></p><p> Here's a closer look at Tesla's top- and bottom-line performance, the key drivers behind those metrics, and some other important take aways from the electric-car maker's third-quarter update on Wednesday afternoon.</p><p><blockquote>以下是特斯拉的营收和利润表现、这些指标背后的关键驱动因素,以及这家电动汽车制造商周三下午第三季度更新的其他一些重要内容。</blockquote></p><p> 1. Revenue jumped</p><p><blockquote>1、营收跃升</blockquote></p><p> Helped by a 73% year-over-year increase in vehicle deliveries, Tesla's revenue increased 57% year over year. The company's sales of its two lower-cost models -- Model 3 and Model Y -- accounted for the bulk of this growth. Combined Model 3 and Y deliveries rose 87% year over year to about 232,000. Total deliveries for the period were a record 241,391.</p><p><blockquote>得益于汽车交付量同比增长73%,特斯拉营收同比增长57%。该公司两款成本较低的车型Model 3和Model Y的销量占了这一增长的大部分。Model 3和Y的总交付量同比增长87%,达到约232,000辆。该期间的总交付量达到创纪录的241,391辆。</blockquote></p><p> 2. A robust gross profit margin</p><p><blockquote>2.强劲的毛利率</blockquote></p><p> Capturing how economies of scale is kicking in for Tesla, its automotive gross margin expanded from 27.7% in the year-ago quarter to 30.5%. This ultimately helped gross profit increase faster than revenue, growing 77%.</p><p><blockquote>特斯拉的汽车毛利率从去年同期的27.7%扩大到30.5%,这体现了规模经济的发挥。这最终帮助毛利润增长快于收入,增长了77%。</blockquote></p><p> 3. Adjusted earnings per share more than doubled</p><p><blockquote>3、调整后每股收益翻倍以上</blockquote></p><p> Tesla's scalable business model was also evident in the company's operating margin, which widened 534 basis points between the third quarter of 2020 and the third quarter of 2021, to 14.6%.</p><p><blockquote>特斯拉可扩展的商业模式也体现在该公司的营业利润率上,该公司的营业利润率在2020年第三季度至2021年第三季度期间扩大了534个基点,达到14.6%。</blockquote></p><p> Improved operating income was \"due to vehicle volume growth and cost reduction,\" Tesla said in its third-quarter update.</p><p><blockquote>特斯拉在第三季度更新中表示,营业收入的改善“是由于车辆销量增长和成本降低”。</blockquote></p><p> Combining Tesla's strong revenue growth with its widening operating margin, the company's non-GAAP(adjusted) earnings per share increased 145% year over year to $1.86. Unadjusted earnings per share rose 433% to $1.44.</p><p><blockquote>结合特斯拉强劲的收入增长和不断扩大的营业利润率,该公司的非GAAP(调整后)每股收益同比增长145%至1.86美元。未经调整的每股收益增长433%至1.44美元。</blockquote></p><p> 4. Over $16 billion of cash</p><p><blockquote>4.超过160亿美元现金</blockquote></p><p> A combination of strong free cash flow ($1.3 billion in Q3 alone) and an already significant cash position meant that Tesla was able to make net debt and finance lease repayments of $1.5 billion and still end the quarter with $16.1 billion in cash.</p><p><blockquote>强劲的自由现金流(仅第三季度就有13亿美元)和本已可观的现金头寸相结合,意味着特斯拉能够偿还15亿美元的净债务和融资租赁,并且在本季度末仍拥有161亿美元的现金。</blockquote></p><p> 5. Rapid growth in energy-storage deployments</p><p><blockquote>5.储能部署快速增长</blockquote></p><p> Tesla's energy-storage deployments during the quarter increased 71% year over year to 1,295 megawatt hours (or about 1.3 gigawatt hours).</p><p><blockquote>特斯拉本季度的储能部署量同比增长71%,达到1,295兆瓦时(约合1.3吉瓦时)。</blockquote></p><p> But Tesla noted in its third-quarter update that this barely taps the surface of where the nascent energy business is headed, as the new Megapack factory Tesla recently broke ground on is supposed to produce 40 gigawatt hours of energy-storage capacity annually. This compares to Tesla's total deployments in the last 12 months of about 3 gigawatts.</p><p><blockquote>但特斯拉在第三季度更新中指出,这几乎没有触及新兴能源业务的发展方向,因为特斯拉最近破土动工的新Megapack工厂预计每年可生产40吉瓦时的储能容量。相比之下,特斯拉过去12个月的总部署量约为3吉瓦。</blockquote></p><p> 6. Guidance for a significant increase in deliveries</p><p><blockquote>6.交付量大幅增加的指导</blockquote></p><p> Finally, Tesla reiterated guidance for deliveries to average a compound annual growth rate of 50% over \"a multi-year horizon,\" despite the company's warnings about \"ongoing supply chain related challenges,\" \"semiconductor shortages,\" and \"congestion at ports.\"</p><p><blockquote>最后,特斯拉重申了“多年期”交付量平均复合年增长率为50%的指导,尽管该公司警告“持续的供应链相关挑战”、“半导体短缺”和“港口拥堵”。”</blockquote></p><p> \"We believe our supply chain, engineering and production teams have been dealing with these global challenges with ingenuity, agility and flexibility that is unparalleled in the automotive industry,\" the company said.</p><p><blockquote>该公司表示:“我们相信,我们的供应链、工程和生产团队一直在以汽车行业无与伦比的独创性、敏捷性和灵活性应对这些全球挑战。”</blockquote></p><p> For Tesla to achieve its full-year guidance for more than 50% growth in deliveries this year, it will need to deliver more than 750,000 units by the end of the year. But with nearly 628,000 vehicles already delivered in 2021, this target appears to be basically in the bag.</p><p><blockquote>特斯拉要实现今年交付量增长超过50%的全年指导,需要在年底前交付超过75万辆。但由于2021年已经交付了近62.8万辆汽车,这一目标似乎基本已成定局。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Q3 Earnings in 6 Must-See Metrics<blockquote>特斯拉第三季度收益的6个必看指标</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Q3 Earnings in 6 Must-See Metrics<blockquote>特斯拉第三季度收益的6个必看指标</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-10-21 19:10</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Expectations were high going into <b>Tesla</b>'s(NASDAQ:TSLA) third-quarter earnings release -- and the company didn't disappoint. Revenue and earnings per share both came in above analysts' average forecasts, setting records for the company.</p><p><blockquote>期望值很高<b>特斯拉</b>(纳斯达克:TSLA)发布了第三季度财报,该公司没有让人失望。营收和每股收益均高于分析师平均预期,创下该公司纪录。</blockquote></p><p> Here's a closer look at Tesla's top- and bottom-line performance, the key drivers behind those metrics, and some other important take aways from the electric-car maker's third-quarter update on Wednesday afternoon.</p><p><blockquote>以下是特斯拉的营收和利润表现、这些指标背后的关键驱动因素,以及这家电动汽车制造商周三下午第三季度更新的其他一些重要内容。</blockquote></p><p> 1. Revenue jumped</p><p><blockquote>1、营收跃升</blockquote></p><p> Helped by a 73% year-over-year increase in vehicle deliveries, Tesla's revenue increased 57% year over year. The company's sales of its two lower-cost models -- Model 3 and Model Y -- accounted for the bulk of this growth. Combined Model 3 and Y deliveries rose 87% year over year to about 232,000. Total deliveries for the period were a record 241,391.</p><p><blockquote>得益于汽车交付量同比增长73%,特斯拉营收同比增长57%。该公司两款成本较低的车型Model 3和Model Y的销量占了这一增长的大部分。Model 3和Y的总交付量同比增长87%,达到约232,000辆。该期间的总交付量达到创纪录的241,391辆。</blockquote></p><p> 2. A robust gross profit margin</p><p><blockquote>2.强劲的毛利率</blockquote></p><p> Capturing how economies of scale is kicking in for Tesla, its automotive gross margin expanded from 27.7% in the year-ago quarter to 30.5%. This ultimately helped gross profit increase faster than revenue, growing 77%.</p><p><blockquote>特斯拉的汽车毛利率从去年同期的27.7%扩大到30.5%,这体现了规模经济的发挥。这最终帮助毛利润增长快于收入,增长了77%。</blockquote></p><p> 3. Adjusted earnings per share more than doubled</p><p><blockquote>3、调整后每股收益翻倍以上</blockquote></p><p> Tesla's scalable business model was also evident in the company's operating margin, which widened 534 basis points between the third quarter of 2020 and the third quarter of 2021, to 14.6%.</p><p><blockquote>特斯拉可扩展的商业模式也体现在该公司的营业利润率上,该公司的营业利润率在2020年第三季度至2021年第三季度期间扩大了534个基点,达到14.6%。</blockquote></p><p> Improved operating income was \"due to vehicle volume growth and cost reduction,\" Tesla said in its third-quarter update.</p><p><blockquote>特斯拉在第三季度更新中表示,营业收入的改善“是由于车辆销量增长和成本降低”。</blockquote></p><p> Combining Tesla's strong revenue growth with its widening operating margin, the company's non-GAAP(adjusted) earnings per share increased 145% year over year to $1.86. Unadjusted earnings per share rose 433% to $1.44.</p><p><blockquote>结合特斯拉强劲的收入增长和不断扩大的营业利润率,该公司的非GAAP(调整后)每股收益同比增长145%至1.86美元。未经调整的每股收益增长433%至1.44美元。</blockquote></p><p> 4. Over $16 billion of cash</p><p><blockquote>4.超过160亿美元现金</blockquote></p><p> A combination of strong free cash flow ($1.3 billion in Q3 alone) and an already significant cash position meant that Tesla was able to make net debt and finance lease repayments of $1.5 billion and still end the quarter with $16.1 billion in cash.</p><p><blockquote>强劲的自由现金流(仅第三季度就有13亿美元)和本已可观的现金头寸相结合,意味着特斯拉能够偿还15亿美元的净债务和融资租赁,并且在本季度末仍拥有161亿美元的现金。</blockquote></p><p> 5. Rapid growth in energy-storage deployments</p><p><blockquote>5.储能部署快速增长</blockquote></p><p> Tesla's energy-storage deployments during the quarter increased 71% year over year to 1,295 megawatt hours (or about 1.3 gigawatt hours).</p><p><blockquote>特斯拉本季度的储能部署量同比增长71%,达到1,295兆瓦时(约合1.3吉瓦时)。</blockquote></p><p> But Tesla noted in its third-quarter update that this barely taps the surface of where the nascent energy business is headed, as the new Megapack factory Tesla recently broke ground on is supposed to produce 40 gigawatt hours of energy-storage capacity annually. This compares to Tesla's total deployments in the last 12 months of about 3 gigawatts.</p><p><blockquote>但特斯拉在第三季度更新中指出,这几乎没有触及新兴能源业务的发展方向,因为特斯拉最近破土动工的新Megapack工厂预计每年可生产40吉瓦时的储能容量。相比之下,特斯拉过去12个月的总部署量约为3吉瓦。</blockquote></p><p> 6. Guidance for a significant increase in deliveries</p><p><blockquote>6.交付量大幅增加的指导</blockquote></p><p> Finally, Tesla reiterated guidance for deliveries to average a compound annual growth rate of 50% over \"a multi-year horizon,\" despite the company's warnings about \"ongoing supply chain related challenges,\" \"semiconductor shortages,\" and \"congestion at ports.\"</p><p><blockquote>最后,特斯拉重申了“多年期”交付量平均复合年增长率为50%的指导,尽管该公司警告“持续的供应链相关挑战”、“半导体短缺”和“港口拥堵”。”</blockquote></p><p> \"We believe our supply chain, engineering and production teams have been dealing with these global challenges with ingenuity, agility and flexibility that is unparalleled in the automotive industry,\" the company said.</p><p><blockquote>该公司表示:“我们相信,我们的供应链、工程和生产团队一直在以汽车行业无与伦比的独创性、敏捷性和灵活性应对这些全球挑战。”</blockquote></p><p> For Tesla to achieve its full-year guidance for more than 50% growth in deliveries this year, it will need to deliver more than 750,000 units by the end of the year. But with nearly 628,000 vehicles already delivered in 2021, this target appears to be basically in the bag.</p><p><blockquote>特斯拉要实现今年交付量增长超过50%的全年指导,需要在年底前交付超过75万辆。但由于2021年已经交付了近62.8万辆汽车,这一目标似乎基本已成定局。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.fool.com/investing/2021/10/21/tesla-earnings-in-6-must-see-metrics/\">Motley Fool</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.fool.com/investing/2021/10/21/tesla-earnings-in-6-must-see-metrics/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119920564","content_text":"Expectations were high going into Tesla's(NASDAQ:TSLA) third-quarter earnings release -- and the company didn't disappoint. Revenue and earnings per share both came in above analysts' average forecasts, setting records for the company.\nHere's a closer look at Tesla's top- and bottom-line performance, the key drivers behind those metrics, and some other important take aways from the electric-car maker's third-quarter update on Wednesday afternoon.\n1. Revenue jumped\nHelped by a 73% year-over-year increase in vehicle deliveries, Tesla's revenue increased 57% year over year. The company's sales of its two lower-cost models -- Model 3 and Model Y -- accounted for the bulk of this growth. Combined Model 3 and Y deliveries rose 87% year over year to about 232,000. Total deliveries for the period were a record 241,391.\n2. A robust gross profit margin\nCapturing how economies of scale is kicking in for Tesla, its automotive gross margin expanded from 27.7% in the year-ago quarter to 30.5%. This ultimately helped gross profit increase faster than revenue, growing 77%.\n3. Adjusted earnings per share more than doubled\nTesla's scalable business model was also evident in the company's operating margin, which widened 534 basis points between the third quarter of 2020 and the third quarter of 2021, to 14.6%.\nImproved operating income was \"due to vehicle volume growth and cost reduction,\" Tesla said in its third-quarter update.\nCombining Tesla's strong revenue growth with its widening operating margin, the company's non-GAAP(adjusted) earnings per share increased 145% year over year to $1.86. Unadjusted earnings per share rose 433% to $1.44.\n4. Over $16 billion of cash\nA combination of strong free cash flow ($1.3 billion in Q3 alone) and an already significant cash position meant that Tesla was able to make net debt and finance lease repayments of $1.5 billion and still end the quarter with $16.1 billion in cash.\n5. Rapid growth in energy-storage deployments\nTesla's energy-storage deployments during the quarter increased 71% year over year to 1,295 megawatt hours (or about 1.3 gigawatt hours).\nBut Tesla noted in its third-quarter update that this barely taps the surface of where the nascent energy business is headed, as the new Megapack factory Tesla recently broke ground on is supposed to produce 40 gigawatt hours of energy-storage capacity annually. This compares to Tesla's total deployments in the last 12 months of about 3 gigawatts.\n6. Guidance for a significant increase in deliveries\nFinally, Tesla reiterated guidance for deliveries to average a compound annual growth rate of 50% over \"a multi-year horizon,\" despite the company's warnings about \"ongoing supply chain related challenges,\" \"semiconductor shortages,\" and \"congestion at ports.\"\n\"We believe our supply chain, engineering and production teams have been dealing with these global challenges with ingenuity, agility and flexibility that is unparalleled in the automotive industry,\" the company said.\nFor Tesla to achieve its full-year guidance for more than 50% growth in deliveries this year, it will need to deliver more than 750,000 units by the end of the year. But with nearly 628,000 vehicles already delivered in 2021, this target appears to be basically in the bag.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1748,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":823649651,"gmtCreate":1633620323994,"gmtModify":1633620324136,"author":{"id":"3581248713273658","authorId":"3581248713273658","name":"LZH97","avatar":"https://static.tigerbbs.com/0a48491665331819a9d1857c6b60743e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581248713273658","authorIdStr":"3581248713273658"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/823649651","repostId":"2173944807","repostType":4,"isVote":1,"tweetType":1,"viewCount":2762,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864192518,"gmtCreate":1633067900726,"gmtModify":1633067900862,"author":{"id":"3581248713273658","authorId":"3581248713273658","name":"LZH97","avatar":"https://static.tigerbbs.com/0a48491665331819a9d1857c6b60743e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581248713273658","authorIdStr":"3581248713273658"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/864192518","repostId":"2172951249","repostType":4,"isVote":1,"tweetType":1,"viewCount":1297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861263765,"gmtCreate":1632498548857,"gmtModify":1632715401825,"author":{"id":"3581248713273658","authorId":"3581248713273658","name":"LZH97","avatar":"https://static.tigerbbs.com/0a48491665331819a9d1857c6b60743e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581248713273658","authorIdStr":"3581248713273658"},"themes":[],"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/861263765","repostId":"1104085778","repostType":4,"repost":{"id":"1104085778","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632498166,"share":"https://www.laohu8.com/m/news/1104085778?lang=zh_CN&edition=full","pubTime":"2021-09-24 23:42","market":"us","language":"en","title":"IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.<blockquote>IPO开盘提醒:Cue Health开盘价为19.2美元,较IPO价格上涨20%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1104085778","media":"Tiger Newspress","summary":"(Sept 24) Cue Health Inc. opens for trading at $19.2, up 20% from IPO price.\n\nCompany & Technology\nS","content":"<p>(Sept 24) <a href=\"https://laohu8.com/S/HLTH\">Cue Health Inc.</a> opens for trading at $19.2, up 20% from IPO price.</p><p><blockquote>(9月24日)<a href=\"https://laohu8.com/S/HLTH\">提示健康公司。</a>开盘价为19.2美元,较IPO价格上涨20%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c7270662a08ec3dac176aa52bf5cbd1a\" tg-width=\"902\" tg-height=\"560\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>Company & Technology</b></p><p><blockquote><b>公司与技术</b></blockquote></p><p> San Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.</p><p><blockquote>总部位于加利福尼亚州圣地亚哥的Cue成立的目的是首先开发新冠肺炎测试套件和用于处理和通信的集成信息平台。</blockquote></p><p> Management is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.</p><p><blockquote>管理层由联合创始人、董事长兼首席执行官Ayub Khattak领导,他自公司成立以来一直在公司工作,并拥有学士学位。加州大学洛杉矶分校数学专业。</blockquote></p><p> The company’s primary offerings in its Cue Integrated Care Platform:</p><p><blockquote>该公司在其Cue综合护理平台中的主要产品:</blockquote></p><p> <ul> <li>Health monitoring system</p><p><blockquote><ul><li>健康监测系统</li></ul></blockquote></p><p></li> <li>Rader</p><p><blockquote><li>雷达</li></blockquote></p><p></li> <li>Cartridge</p><p><blockquote><li>弹壳</li></blockquote></p><p></li> <li>Wand</p><p><blockquote><li>墙</li></blockquote></p><p></li> <li>Data</p><p><blockquote><li>数据</li></blockquote></p><p></li> <li>Delivery apps</p><p><blockquote><li>交付应用程序</li></blockquote></p><p></li> <li>Enterprise dashboard</p><p><blockquote><li>企业仪表板</li></blockquote></p><p></li> <li>Ecosystem integrations</p><p><blockquote><li>生态系统集成</li></blockquote></p><p></li> </ul> Cue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.</p><p><blockquote>Cue已经获得了包括ACME Capital、Cove Investors、德诚资本中国生命科学、Madrone和NVGA I在内的投资者至少1.76亿美元的股权投资。</blockquote></p><p> <b>Customer/User Acquisition</b></p><p><blockquote><b>客户/用户获取</b></blockquote></p><p> The company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.</p><p><blockquote>该公司通过其专注于医疗保健提供商、大型企业和公共部门客户的内部直销团队寻求医疗保健提供商关系。</blockquote></p><p> Management expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.</p><p><blockquote>管理层预计,2021年客户对其COVID-19检测试剂盒的需求将超过其生产能力。</blockquote></p><p> Sales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:</p><p><blockquote>销售及营销开支佔总收入的百分比随着收入急剧增加而变化,如下图所示:</blockquote></p><p> <table> <tbody> <tr> <td><b>Sales and Marketing</b></p><p><blockquote><table><tbody><tr><td><b>销售及市场推广</b></td></tr></tbody></table></blockquote></p><p></td> <td><b>Expenses vs. Revenue</b></p><p><blockquote><td><b>费用与收入</b></td></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Percentage</p><p><blockquote><td>百分比</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>1.0%</p><p><blockquote><td>1.0%</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>3.1%</p><p><blockquote><td>3.1%</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>1.3%</p><p><blockquote><td>1.3%</td></blockquote></p><p></td> </tr> </tbody> </table> The Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:</p><p><blockquote>销售和营销效率率(定义为每美元销售和营销支出产生多少美元的额外新收入)在最近一个报告期内为100.5倍,如下表所示:</blockquote></p><p> <table> <tbody> <tr> <td><b>Sales and Marketing</b></p><p><blockquote><table><tbody><tr><td><b>销售及市场推广</b></td></tr></tbody></table></blockquote></p><p></td> <td><b>Efficiency Rate</b></p><p><blockquote><td><b>效率率</b></td></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Multiple</p><p><blockquote><td>多个的</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>100.5</p><p><blockquote><td>100.5</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>22.9</p><p><blockquote><td>22.9</td></blockquote></p><p></td> </tr> </tbody> </table> <b>Market & Competition</b></p><p><blockquote><b>市场与竞争</b></blockquote></p><p> According to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.</p><p><blockquote>根据Grand View Research的2020年市场研究报告,2020年新冠肺炎检测试剂盒的全球市场估计为32.8亿美元,预计到2027年将达到50亿美元。</blockquote></p><p> This represents a forecast CAGR of 5.05% from 2021 to 2027.</p><p><blockquote>这意味着2021年至2027年的预测复合年增长率为5.05%。</blockquote></p><p> The main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.</p><p><blockquote>这一预期增长的主要驱动力是全球对所有类型测试服务需求的强劲增长。</blockquote></p><p> Also, below is a chart showing the market share of use of detection kits by end-user type:</p><p><blockquote>此外,下图显示了按最终用户类型划分的检测试剂盒使用的市场份额:</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4b7fc60b336bae7685e08132f8176b57\" tg-width=\"1158\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> (Source)</p><p><blockquote>(资料来源)</blockquote></p><p> Major competitive or other industry participants include:</p><p><blockquote>主要竞争对手或其他行业参与者包括:</blockquote></p><p> <ul> <li>Abbott Laboratories(NYSE:ABT)</p><p><blockquote><ul><li>雅培实验室(纽约证券交易所代码:ABT)</li></ul></blockquote></p><p></li> <li>Becton, Dickinson(NYSE:BDX)</p><p><blockquote><li>迪金森贝克顿(纽约证券交易所代码:BDX)</li></blockquote></p><p></li> <li>bioMerieux(OTCPK:BMXMF)</p><p><blockquote><li>生物梅里埃(OTCPK:BMXMF)</li></blockquote></p><p></li> <li>Bio-Rad Laboratories(NYSE:BIO)</p><p><blockquote><li>Bio-Rad实验室(纽约证券交易所股票代码:BIO)</li></blockquote></p><p></li> <li>Danaher(NYSE:DHR)</p><p><blockquote><li>丹纳赫(纽约证券交易所代码:DHR)</li></blockquote></p><p></li> <li>Ellume Limited</p><p><blockquote><li>Ellume有限公司</li></blockquote></p><p></li> <li>Everly Health</p><p><blockquote><li>艾弗利健康</li></blockquote></p><p></li> <li>Roche(OTCQX:RHHBY)(OTCQX:RHHBF)</p><p><blockquote><li>罗氏(OTCQX:RHHBY)(OTCQX:RHHBF)</li></blockquote></p><p></li> <li>Fluidigm(NASDAQ:FLDM)</p><p><blockquote><li>Fluidigm(纳斯达克:FLDM)</li></blockquote></p><p></li> <li>GenMark Diagnostics(NASDAQ:GNMK)</p><p><blockquote><li>GenMark Diagnostics(纳斯达克:GNMK)</li></blockquote></p><p></li> <li>Others</p><p><blockquote><li>其他</li></blockquote></p><p></li> </ul> <b>Financial Performance</b></p><p><blockquote><b>财务表现</b></blockquote></p><p> Cue’s recent financial results can be summarized as follows:</p><p><blockquote>Cue近期财务业绩可总结如下:</blockquote></p><p> <ul> <li>Sharply growing top line revenue</p><p><blockquote><ul><li>营收急剧增长</li></ul></blockquote></p><p></li> <li>Increasing gross profit and variable gross margin</p><p><blockquote><li>增加毛利及可变毛利率</li></blockquote></p><p></li> <li>A swing to operating profit and net income</p><p><blockquote><li>营业利润和净利润的波动</li></blockquote></p><p></li> <li>Variable cash flow from operations</p><p><blockquote><li>经营活动产生的可变现金流量</li></blockquote></p><p></li> </ul> Below are relevant financial results derived from the firm’s registration statement:</p><p><blockquote>以下是来自公司注册声明的相关财务业绩:</blockquote></p><p> <table> <colgroup></colgroup> <tbody> <tr> <td><b>Total Revenue</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>收入总额</b></td></tr></tbody></table></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Total Revenue</p><p><blockquote><td>收入总额</td></blockquote></p><p></td> <td>% Variance vs. Prior</p><p><blockquote><td>与既往相比的%差异</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>$ 201,922,000</p><p><blockquote><td>$201,922,000</td></blockquote></p><p></td> <td>3971.0%</p><p><blockquote><td>3971.0%</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>$ 22,953,000</p><p><blockquote><td>$22,953,000</td></blockquote></p><p></td> <td>246.4%</p><p><blockquote><td>246.4%</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>$ 6,626,000</p><p><blockquote><td>$6,626,000</td></blockquote></p><p></td> </tr> <tr></tr> <tr> <td><b>Gross Profit (Loss)</b></p><p><blockquote><tr></tr><tr><td><b>毛利(亏损)</b></td></tr></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Gross Profit (Loss)</p><p><blockquote><td>毛利(亏损)</td></blockquote></p><p></td> <td>% Variance vs. Prior</p><p><blockquote><td>与既往相比的%差异</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>$ 116,745,000</p><p><blockquote><td>$116,745,000</td></blockquote></p><p></td> <td>2253.7%</p><p><blockquote><td>2253.7%</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>$ 8,002,000</p><p><blockquote><td>$8,002,000</td></blockquote></p><p></td> <td>20.8%</p><p><blockquote><td>20.8%</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>$ 6,626,000</p><p><blockquote><td>$6,626,000</td></blockquote></p><p></p><p></td> </tr> <tr></tr> <tr> <td><b>Gross Margin</b></p><p><blockquote><tr></tr><tr><td><b>毛利率</b></td></tr></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Gross Margin</p><p><blockquote><td>毛利率</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>57.82%</p><p><blockquote><td>57.82%</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>34.86%</p><p><blockquote><td>34.86%</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>100.00%</p><p><blockquote><td>100.00%</td></blockquote></p><p></td> </tr> <tr></tr> <tr> <td><b>Operating Profit (Loss)</b></p><p><blockquote><tr></tr><tr><td><b>经营溢利(亏损)</b></td></tr></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Operating Profit (Loss)</p><p><blockquote><td>经营溢利(亏损)</td></blockquote></p><p></td> <td>Operating Margin</p><p><blockquote><td>营业利润率</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>$ 79,463,000</p><p><blockquote><td>$79,463,000</td></blockquote></p><p></td> <td>39.4%</p><p><blockquote><td>39.4%</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>$ (45,126,000)</p><p><blockquote><td>$(45,126,000)</td></blockquote></p><p></td> <td>-196.6%</p><p><blockquote><td>-196.6%</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>$ (20,767,000)</p><p><blockquote><td>$(20,767,000)</td></blockquote></p><p></td> <td>-313.4%</p><p><blockquote><td>-313.4%</td></blockquote></p><p></td> </tr> <tr></tr> <tr> <td><b>Net Income (Loss)</b></p><p><blockquote><tr></tr><tr><td><b>净利润(亏损)</b></td></tr></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Net Income (Loss)</p><p><blockquote><td>净利润(亏损)</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>$ 32,840,000</p><p><blockquote><td>$32,840,000</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>$ (47,352,000)</p><p><blockquote><td>$(47,352,000)</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>$ (20,606,000)</p><p><blockquote><td>$(20,606,000)</td></blockquote></p><p></td> </tr> <tr></tr> <tr> <td><b>Cash Flow From Operations</b></p><p><blockquote><tr></tr><tr><td><b>经营所得现金流量</b></td></tr></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Cash Flow From Operations</p><p><blockquote><td>经营所得现金流量</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>$ (37,812,000)</p><p><blockquote><td>$(37,812,000)</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>$ 92,655,000</p><p><blockquote><td>$92,655,000</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>$ (12,996,000)</p><p><blockquote><td>$(12,996,000)</td></blockquote></p><p></td> </tr> </tbody> </table> As of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.</p><p><blockquote>截至2021年6月30日,Cue拥有2.463亿美元现金,总负债为5.163亿美元。</blockquote></p><p> Free cash flow during the twelve months ended June 30, 2021, was negative ($60 million).</p><p><blockquote>截至2021年6月30日的12个月内,自由现金流为负(6000万美元)。</blockquote></p><p> <b>Valuation Metrics</b></p><p><blockquote><b>估值指标</b></blockquote></p><p> Below is a table of relevant capitalization and valuation figures for the company:</p><p><blockquote>下表为本公司的相关资本化及估值数字:</blockquote></p><p> <table> <colgroup></colgroup> <tbody> <tr> <td><b>Measure [TTM]</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>测量[TTM]</b></td></tr></tbody></table></blockquote></p><p></td> <td><b>Amount</b></p><p><blockquote><td><b>数量</b></td></blockquote></p><p></td> </tr> <tr> <td>Market Capitalization at IPO</p><p><blockquote><tr><td>IPO时的市值</td></tr></blockquote></p><p></td> <td>$2,299,981,232</p><p><blockquote><td>$2,299,981,232</td></blockquote></p><p></td> </tr> <tr> <td>Enterprise Value</p><p><blockquote><tr><td>企业价值</td></tr></blockquote></p><p></td> <td>$1,874,455,232</p><p><blockquote><td>$1,874,455,232</td></blockquote></p><p></td> </tr> <tr> <td>Price / Sales</p><p><blockquote><tr><td>价格/销售额</td></tr></blockquote></p><p></td> <td>10.46</p><p><blockquote><td>10.46</td></blockquote></p><p></td> </tr> <tr> <td>EV / Revenue</p><p><blockquote><tr><td>EV/收入</td></tr></blockquote></p><p></td> <td>8.52</p><p><blockquote><td>8.52</td></blockquote></p><p></td> </tr> <tr> <td>EV / EBITDA</p><p><blockquote><tr><td>EV/EBITDA</td></tr></blockquote></p><p></td> <td>35.46</p><p><blockquote><td>35.46</td></blockquote></p><p></td> </tr> <tr> <td>Earnings Per Share</p><p><blockquote><tr><td>每股盈利</td></tr></blockquote></p><p></td> <td>$0.03</p><p><blockquote><td>$0.03</td></blockquote></p><p></td> </tr> <tr> <td>Float To Outstanding Shares Ratio</p><p><blockquote><tr><td>流通股与流通股比率</td></tr></blockquote></p><p></td> <td>8.70%</p><p><blockquote><td>8.70%</td></blockquote></p><p></td> </tr> <tr> <td>Proposed IPO Midpoint Price per Share</p><p><blockquote><tr><td>建议IPO每股中点价格</td></tr></blockquote></p><p></td> <td>$16.00</p><p><blockquote><td>$16.00</td></blockquote></p><p></td> </tr> <tr> <td>Net Free Cash Flow</p><p><blockquote><tr><td>净自由现金流</td></tr></blockquote></p><p></td> <td>-$59,920,000</p><p><blockquote><td>-$59,920,000</td></blockquote></p><p></td> </tr> <tr> <td>Free Cash Flow Yield Per Share</p><p><blockquote><tr><td>每股自由现金流收益率</td></tr></blockquote></p><p></td> <td>-2.61%</p><p><blockquote><td>-2.61%</td></blockquote></p><p></td> </tr> <tr> <td>Revenue Growth Rate</p><p><blockquote><tr><td>收入增长率</td></tr></blockquote></p><p></td> <td>3971.01%</p><p><blockquote><td>3971.01%</td></blockquote></p><p></td> </tr> </tbody> </table> As a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:</p><p><blockquote>作为参考,与Cue相当的潜在部分和不完美的公共将是Bio-Rad(BIO);以下是其主要估值指标的比较:</blockquote></p><p> <table> <colgroup></colgroup> <tbody> <tr> <td><b>Metric</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>公制</b></td></tr></tbody></table></blockquote></p><p></td> <td><b>Bio-Rad (BIO)</b></p><p><blockquote><td><b>Bio-Rad(生物)</b></td></blockquote></p><p></td> <td><b>Cue Health (HLTH)</b></p><p><blockquote><td><b>提示健康(HLTH)</b></td></blockquote></p><p></td> <td><b>Variance</b></p><p><blockquote><td><b>差异</b></td></blockquote></p><p></td> </tr> <tr> <td>Price / Sales</p><p><blockquote><tr><td>价格/销售额</td></tr></blockquote></p><p></td> <td>8.15</p><p><blockquote><td>8.15</td></blockquote></p><p></td> <td>10.46</p><p><blockquote><td>10.46</td></blockquote></p><p></td> <td>28.3%</p><p><blockquote><td>28.3%</td></blockquote></p><p></td> </tr> <tr> <td>EV / Revenue</p><p><blockquote><tr><td>EV/收入</td></tr></blockquote></p><p></td> <td>7.82</p><p><blockquote><td>7.82</td></blockquote></p><p></td> <td>8.52</p><p><blockquote><td>8.52</td></blockquote></p><p></td> <td>9.0%</p><p><blockquote><td>9.0%</td></blockquote></p><p></td> </tr> <tr> <td>EV / EBITDA</p><p><blockquote><tr><td>EV/EBITDA</td></tr></blockquote></p><p></td> <td>31.66</p><p><blockquote><td>31.66</td></blockquote></p><p></td> <td>35.46</p><p><blockquote><td>35.46</td></blockquote></p><p></td> <td>12.0%</p><p><blockquote><td>12.0%</td></blockquote></p><p></td> </tr> <tr> <td>Earnings Per Share</p><p><blockquote><tr><td>每股盈利</td></tr></blockquote></p><p></td> <td>$134.05</p><p><blockquote><td>$134.05</td></blockquote></p><p></td> <td>$0.03</p><p><blockquote><td>$0.03</td></blockquote></p><p></td> <td>-100.0%</p><p><blockquote><td>-100.0%</td></blockquote></p><p></td> </tr> <tr> <td>Revenue Growth Rate</p><p><blockquote><tr><td>收入增长率</td></tr></blockquote></p><p></td> <td>25.6%</p><p><blockquote><td>25.6%</td></blockquote></p><p></td> <td>3971.01%</p><p><blockquote><td>3971.01%</td></blockquote></p><p></td> <td>15436.03%</p><p><blockquote><td>15436.03%</td></blockquote></p><p></td> </tr> <tr> <td>(Glossary Of Terms)</p><p><blockquote><tr><td>(术语表)</td></tr></blockquote></p><p></td> </tr> </tbody> </table> <b>Commentary</b></p><p><blockquote><b>评论</b></blockquote></p><p> Cue is seeking public investment capital to further scale its commercialization operations as well as continue its R & D efforts.</p><p><blockquote>Cue正在寻求公共投资资本,以进一步扩大其商业化业务并继续其研发工作。</blockquote></p><p> The company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations</p><p><blockquote>该公司的财务数据显示,营收大幅增长,毛利润和可变毛利率强劲增长,营业利润和净利润出现波动,经营活动产生或使用的现金流高度波动</blockquote></p><p> Free cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).</p><p><blockquote>截至2021年6月30日的12个月的自由现金流是令人瞠目结舌的负值(6000万美元)。</blockquote></p><p> Sales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.</p><p><blockquote>销售和营销费用占总收入的百分比随着收入的急剧增加而波动;在最近的报告期内,其销售和营销效率高达100.5倍。</blockquote></p><p> The market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.</p><p><blockquote>新冠肺炎和相关检测试剂盒平台的市场机会很大,并且在未来几年可能会以高增长率增长,因为世界各国在最近的全球疫情之后寻求增强其检测能力。</blockquote></p><p></p><p> Goldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p><p><blockquote>高盛是首席承销商,该公司在过去12个月内牵头的IPO自IPO以来的平均回报率为39.9%。这是期内所有主要承销商的中等表现。</blockquote></p><p> The primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.</p><p><blockquote>该公司现在面临的主要风险是,它本质上是一家单一产品公司,因此其收入基础高度集中。</blockquote></p><p> As for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.</p><p><blockquote>至于估值,与部分竞争对手Bio-Rad Laboratories相比,IPO的收入倍数估值合理,尽管Cue在收入基础低得多的情况下以高得多的增长率增长,因此这种比较充其量是紧张的。</blockquote></p><p> Given Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.</p><p><blockquote>鉴于Cue的增长轨迹、盈利能力和合理的IPO估值,此次IPO值得考虑。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.<blockquote>IPO开盘提醒:Cue Health开盘价为19.2美元,较IPO价格上涨20%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO opening reminder: Cue Health opens for trading at $19.2, up 20% from IPO price.<blockquote>IPO开盘提醒:Cue Health开盘价为19.2美元,较IPO价格上涨20%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-24 23:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Sept 24) <a href=\"https://laohu8.com/S/HLTH\">Cue Health Inc.</a> opens for trading at $19.2, up 20% from IPO price.</p><p><blockquote>(9月24日)<a href=\"https://laohu8.com/S/HLTH\">提示健康公司。</a>开盘价为19.2美元,较IPO价格上涨20%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c7270662a08ec3dac176aa52bf5cbd1a\" tg-width=\"902\" tg-height=\"560\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>Company & Technology</b></p><p><blockquote><b>公司与技术</b></blockquote></p><p> San Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.</p><p><blockquote>总部位于加利福尼亚州圣地亚哥的Cue成立的目的是首先开发新冠肺炎测试套件和用于处理和通信的集成信息平台。</blockquote></p><p> Management is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.</p><p><blockquote>管理层由联合创始人、董事长兼首席执行官Ayub Khattak领导,他自公司成立以来一直在公司工作,并拥有学士学位。加州大学洛杉矶分校数学专业。</blockquote></p><p> The company’s primary offerings in its Cue Integrated Care Platform:</p><p><blockquote>该公司在其Cue综合护理平台中的主要产品:</blockquote></p><p> <ul> <li>Health monitoring system</p><p><blockquote><ul><li>健康监测系统</li></ul></blockquote></p><p></li> <li>Rader</p><p><blockquote><li>雷达</li></blockquote></p><p></li> <li>Cartridge</p><p><blockquote><li>弹壳</li></blockquote></p><p></li> <li>Wand</p><p><blockquote><li>墙</li></blockquote></p><p></li> <li>Data</p><p><blockquote><li>数据</li></blockquote></p><p></li> <li>Delivery apps</p><p><blockquote><li>交付应用程序</li></blockquote></p><p></li> <li>Enterprise dashboard</p><p><blockquote><li>企业仪表板</li></blockquote></p><p></li> <li>Ecosystem integrations</p><p><blockquote><li>生态系统集成</li></blockquote></p><p></li> </ul> Cue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.</p><p><blockquote>Cue已经获得了包括ACME Capital、Cove Investors、德诚资本中国生命科学、Madrone和NVGA I在内的投资者至少1.76亿美元的股权投资。</blockquote></p><p> <b>Customer/User Acquisition</b></p><p><blockquote><b>客户/用户获取</b></blockquote></p><p> The company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.</p><p><blockquote>该公司通过其专注于医疗保健提供商、大型企业和公共部门客户的内部直销团队寻求医疗保健提供商关系。</blockquote></p><p> Management expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.</p><p><blockquote>管理层预计,2021年客户对其COVID-19检测试剂盒的需求将超过其生产能力。</blockquote></p><p> Sales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:</p><p><blockquote>销售及营销开支佔总收入的百分比随着收入急剧增加而变化,如下图所示:</blockquote></p><p> <table> <tbody> <tr> <td><b>Sales and Marketing</b></p><p><blockquote><table><tbody><tr><td><b>销售及市场推广</b></td></tr></tbody></table></blockquote></p><p></td> <td><b>Expenses vs. Revenue</b></p><p><blockquote><td><b>费用与收入</b></td></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Percentage</p><p><blockquote><td>百分比</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>1.0%</p><p><blockquote><td>1.0%</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>3.1%</p><p><blockquote><td>3.1%</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>1.3%</p><p><blockquote><td>1.3%</td></blockquote></p><p></td> </tr> </tbody> </table> The Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:</p><p><blockquote>销售和营销效率率(定义为每美元销售和营销支出产生多少美元的额外新收入)在最近一个报告期内为100.5倍,如下表所示:</blockquote></p><p> <table> <tbody> <tr> <td><b>Sales and Marketing</b></p><p><blockquote><table><tbody><tr><td><b>销售及市场推广</b></td></tr></tbody></table></blockquote></p><p></td> <td><b>Efficiency Rate</b></p><p><blockquote><td><b>效率率</b></td></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Multiple</p><p><blockquote><td>多个的</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>100.5</p><p><blockquote><td>100.5</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>22.9</p><p><blockquote><td>22.9</td></blockquote></p><p></td> </tr> </tbody> </table> <b>Market & Competition</b></p><p><blockquote><b>市场与竞争</b></blockquote></p><p> According to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.</p><p><blockquote>根据Grand View Research的2020年市场研究报告,2020年新冠肺炎检测试剂盒的全球市场估计为32.8亿美元,预计到2027年将达到50亿美元。</blockquote></p><p> This represents a forecast CAGR of 5.05% from 2021 to 2027.</p><p><blockquote>这意味着2021年至2027年的预测复合年增长率为5.05%。</blockquote></p><p> The main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.</p><p><blockquote>这一预期增长的主要驱动力是全球对所有类型测试服务需求的强劲增长。</blockquote></p><p> Also, below is a chart showing the market share of use of detection kits by end-user type:</p><p><blockquote>此外,下图显示了按最终用户类型划分的检测试剂盒使用的市场份额:</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4b7fc60b336bae7685e08132f8176b57\" tg-width=\"1158\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> (Source)</p><p><blockquote>(资料来源)</blockquote></p><p> Major competitive or other industry participants include:</p><p><blockquote>主要竞争对手或其他行业参与者包括:</blockquote></p><p> <ul> <li>Abbott Laboratories(NYSE:ABT)</p><p><blockquote><ul><li>雅培实验室(纽约证券交易所代码:ABT)</li></ul></blockquote></p><p></li> <li>Becton, Dickinson(NYSE:BDX)</p><p><blockquote><li>迪金森贝克顿(纽约证券交易所代码:BDX)</li></blockquote></p><p></li> <li>bioMerieux(OTCPK:BMXMF)</p><p><blockquote><li>生物梅里埃(OTCPK:BMXMF)</li></blockquote></p><p></li> <li>Bio-Rad Laboratories(NYSE:BIO)</p><p><blockquote><li>Bio-Rad实验室(纽约证券交易所股票代码:BIO)</li></blockquote></p><p></li> <li>Danaher(NYSE:DHR)</p><p><blockquote><li>丹纳赫(纽约证券交易所代码:DHR)</li></blockquote></p><p></li> <li>Ellume Limited</p><p><blockquote><li>Ellume有限公司</li></blockquote></p><p></li> <li>Everly Health</p><p><blockquote><li>艾弗利健康</li></blockquote></p><p></li> <li>Roche(OTCQX:RHHBY)(OTCQX:RHHBF)</p><p><blockquote><li>罗氏(OTCQX:RHHBY)(OTCQX:RHHBF)</li></blockquote></p><p></li> <li>Fluidigm(NASDAQ:FLDM)</p><p><blockquote><li>Fluidigm(纳斯达克:FLDM)</li></blockquote></p><p></li> <li>GenMark Diagnostics(NASDAQ:GNMK)</p><p><blockquote><li>GenMark Diagnostics(纳斯达克:GNMK)</li></blockquote></p><p></li> <li>Others</p><p><blockquote><li>其他</li></blockquote></p><p></li> </ul> <b>Financial Performance</b></p><p><blockquote><b>财务表现</b></blockquote></p><p> Cue’s recent financial results can be summarized as follows:</p><p><blockquote>Cue近期财务业绩可总结如下:</blockquote></p><p> <ul> <li>Sharply growing top line revenue</p><p><blockquote><ul><li>营收急剧增长</li></ul></blockquote></p><p></li> <li>Increasing gross profit and variable gross margin</p><p><blockquote><li>增加毛利及可变毛利率</li></blockquote></p><p></li> <li>A swing to operating profit and net income</p><p><blockquote><li>营业利润和净利润的波动</li></blockquote></p><p></li> <li>Variable cash flow from operations</p><p><blockquote><li>经营活动产生的可变现金流量</li></blockquote></p><p></li> </ul> Below are relevant financial results derived from the firm’s registration statement:</p><p><blockquote>以下是来自公司注册声明的相关财务业绩:</blockquote></p><p> <table> <colgroup></colgroup> <tbody> <tr> <td><b>Total Revenue</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>收入总额</b></td></tr></tbody></table></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Total Revenue</p><p><blockquote><td>收入总额</td></blockquote></p><p></td> <td>% Variance vs. Prior</p><p><blockquote><td>与既往相比的%差异</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>$ 201,922,000</p><p><blockquote><td>$201,922,000</td></blockquote></p><p></td> <td>3971.0%</p><p><blockquote><td>3971.0%</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>$ 22,953,000</p><p><blockquote><td>$22,953,000</td></blockquote></p><p></td> <td>246.4%</p><p><blockquote><td>246.4%</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>$ 6,626,000</p><p><blockquote><td>$6,626,000</td></blockquote></p><p></td> </tr> <tr></tr> <tr> <td><b>Gross Profit (Loss)</b></p><p><blockquote><tr></tr><tr><td><b>毛利(亏损)</b></td></tr></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Gross Profit (Loss)</p><p><blockquote><td>毛利(亏损)</td></blockquote></p><p></td> <td>% Variance vs. Prior</p><p><blockquote><td>与既往相比的%差异</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>$ 116,745,000</p><p><blockquote><td>$116,745,000</td></blockquote></p><p></td> <td>2253.7%</p><p><blockquote><td>2253.7%</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>$ 8,002,000</p><p><blockquote><td>$8,002,000</td></blockquote></p><p></td> <td>20.8%</p><p><blockquote><td>20.8%</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>$ 6,626,000</p><p><blockquote><td>$6,626,000</td></blockquote></p><p></p><p></td> </tr> <tr></tr> <tr> <td><b>Gross Margin</b></p><p><blockquote><tr></tr><tr><td><b>毛利率</b></td></tr></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Gross Margin</p><p><blockquote><td>毛利率</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>57.82%</p><p><blockquote><td>57.82%</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>34.86%</p><p><blockquote><td>34.86%</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>100.00%</p><p><blockquote><td>100.00%</td></blockquote></p><p></td> </tr> <tr></tr> <tr> <td><b>Operating Profit (Loss)</b></p><p><blockquote><tr></tr><tr><td><b>经营溢利(亏损)</b></td></tr></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Operating Profit (Loss)</p><p><blockquote><td>经营溢利(亏损)</td></blockquote></p><p></td> <td>Operating Margin</p><p><blockquote><td>营业利润率</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>$ 79,463,000</p><p><blockquote><td>$79,463,000</td></blockquote></p><p></td> <td>39.4%</p><p><blockquote><td>39.4%</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>$ (45,126,000)</p><p><blockquote><td>$(45,126,000)</td></blockquote></p><p></td> <td>-196.6%</p><p><blockquote><td>-196.6%</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>$ (20,767,000)</p><p><blockquote><td>$(20,767,000)</td></blockquote></p><p></td> <td>-313.4%</p><p><blockquote><td>-313.4%</td></blockquote></p><p></td> </tr> <tr></tr> <tr> <td><b>Net Income (Loss)</b></p><p><blockquote><tr></tr><tr><td><b>净利润(亏损)</b></td></tr></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Net Income (Loss)</p><p><blockquote><td>净利润(亏损)</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>$ 32,840,000</p><p><blockquote><td>$32,840,000</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>$ (47,352,000)</p><p><blockquote><td>$(47,352,000)</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>$ (20,606,000)</p><p><blockquote><td>$(20,606,000)</td></blockquote></p><p></td> </tr> <tr></tr> <tr> <td><b>Cash Flow From Operations</b></p><p><blockquote><tr></tr><tr><td><b>经营所得现金流量</b></td></tr></blockquote></p><p></td> </tr> <tr> <td>Period</p><p><blockquote><tr><td>周期</td></tr></blockquote></p><p></td> <td>Cash Flow From Operations</p><p><blockquote><td>经营所得现金流量</td></blockquote></p><p></td> </tr> <tr> <td>Six Mos. Ended June 30, 2021</p><p><blockquote><tr><td>六个月。截至2021年6月30日止</td></tr></blockquote></p><p></td> <td>$ (37,812,000)</p><p><blockquote><td>$(37,812,000)</td></blockquote></p><p></td> </tr> <tr> <td>2020</p><p><blockquote><tr><td>2020</td></tr></blockquote></p><p></td> <td>$ 92,655,000</p><p><blockquote><td>$92,655,000</td></blockquote></p><p></td> </tr> <tr> <td>2019</p><p><blockquote><tr><td>2019</td></tr></blockquote></p><p></td> <td>$ (12,996,000)</p><p><blockquote><td>$(12,996,000)</td></blockquote></p><p></td> </tr> </tbody> </table> As of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.</p><p><blockquote>截至2021年6月30日,Cue拥有2.463亿美元现金,总负债为5.163亿美元。</blockquote></p><p> Free cash flow during the twelve months ended June 30, 2021, was negative ($60 million).</p><p><blockquote>截至2021年6月30日的12个月内,自由现金流为负(6000万美元)。</blockquote></p><p> <b>Valuation Metrics</b></p><p><blockquote><b>估值指标</b></blockquote></p><p> Below is a table of relevant capitalization and valuation figures for the company:</p><p><blockquote>下表为本公司的相关资本化及估值数字:</blockquote></p><p> <table> <colgroup></colgroup> <tbody> <tr> <td><b>Measure [TTM]</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>测量[TTM]</b></td></tr></tbody></table></blockquote></p><p></td> <td><b>Amount</b></p><p><blockquote><td><b>数量</b></td></blockquote></p><p></td> </tr> <tr> <td>Market Capitalization at IPO</p><p><blockquote><tr><td>IPO时的市值</td></tr></blockquote></p><p></td> <td>$2,299,981,232</p><p><blockquote><td>$2,299,981,232</td></blockquote></p><p></td> </tr> <tr> <td>Enterprise Value</p><p><blockquote><tr><td>企业价值</td></tr></blockquote></p><p></td> <td>$1,874,455,232</p><p><blockquote><td>$1,874,455,232</td></blockquote></p><p></td> </tr> <tr> <td>Price / Sales</p><p><blockquote><tr><td>价格/销售额</td></tr></blockquote></p><p></td> <td>10.46</p><p><blockquote><td>10.46</td></blockquote></p><p></td> </tr> <tr> <td>EV / Revenue</p><p><blockquote><tr><td>EV/收入</td></tr></blockquote></p><p></td> <td>8.52</p><p><blockquote><td>8.52</td></blockquote></p><p></td> </tr> <tr> <td>EV / EBITDA</p><p><blockquote><tr><td>EV/EBITDA</td></tr></blockquote></p><p></td> <td>35.46</p><p><blockquote><td>35.46</td></blockquote></p><p></td> </tr> <tr> <td>Earnings Per Share</p><p><blockquote><tr><td>每股盈利</td></tr></blockquote></p><p></td> <td>$0.03</p><p><blockquote><td>$0.03</td></blockquote></p><p></td> </tr> <tr> <td>Float To Outstanding Shares Ratio</p><p><blockquote><tr><td>流通股与流通股比率</td></tr></blockquote></p><p></td> <td>8.70%</p><p><blockquote><td>8.70%</td></blockquote></p><p></td> </tr> <tr> <td>Proposed IPO Midpoint Price per Share</p><p><blockquote><tr><td>建议IPO每股中点价格</td></tr></blockquote></p><p></td> <td>$16.00</p><p><blockquote><td>$16.00</td></blockquote></p><p></td> </tr> <tr> <td>Net Free Cash Flow</p><p><blockquote><tr><td>净自由现金流</td></tr></blockquote></p><p></td> <td>-$59,920,000</p><p><blockquote><td>-$59,920,000</td></blockquote></p><p></td> </tr> <tr> <td>Free Cash Flow Yield Per Share</p><p><blockquote><tr><td>每股自由现金流收益率</td></tr></blockquote></p><p></td> <td>-2.61%</p><p><blockquote><td>-2.61%</td></blockquote></p><p></td> </tr> <tr> <td>Revenue Growth Rate</p><p><blockquote><tr><td>收入增长率</td></tr></blockquote></p><p></td> <td>3971.01%</p><p><blockquote><td>3971.01%</td></blockquote></p><p></td> </tr> </tbody> </table> As a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:</p><p><blockquote>作为参考,与Cue相当的潜在部分和不完美的公共将是Bio-Rad(BIO);以下是其主要估值指标的比较:</blockquote></p><p> <table> <colgroup></colgroup> <tbody> <tr> <td><b>Metric</b></p><p><blockquote><table><colgroup></colgroup><tbody><tr><td><b>公制</b></td></tr></tbody></table></blockquote></p><p></td> <td><b>Bio-Rad (BIO)</b></p><p><blockquote><td><b>Bio-Rad(生物)</b></td></blockquote></p><p></td> <td><b>Cue Health (HLTH)</b></p><p><blockquote><td><b>提示健康(HLTH)</b></td></blockquote></p><p></td> <td><b>Variance</b></p><p><blockquote><td><b>差异</b></td></blockquote></p><p></td> </tr> <tr> <td>Price / Sales</p><p><blockquote><tr><td>价格/销售额</td></tr></blockquote></p><p></td> <td>8.15</p><p><blockquote><td>8.15</td></blockquote></p><p></td> <td>10.46</p><p><blockquote><td>10.46</td></blockquote></p><p></td> <td>28.3%</p><p><blockquote><td>28.3%</td></blockquote></p><p></td> </tr> <tr> <td>EV / Revenue</p><p><blockquote><tr><td>EV/收入</td></tr></blockquote></p><p></td> <td>7.82</p><p><blockquote><td>7.82</td></blockquote></p><p></td> <td>8.52</p><p><blockquote><td>8.52</td></blockquote></p><p></td> <td>9.0%</p><p><blockquote><td>9.0%</td></blockquote></p><p></td> </tr> <tr> <td>EV / EBITDA</p><p><blockquote><tr><td>EV/EBITDA</td></tr></blockquote></p><p></td> <td>31.66</p><p><blockquote><td>31.66</td></blockquote></p><p></td> <td>35.46</p><p><blockquote><td>35.46</td></blockquote></p><p></td> <td>12.0%</p><p><blockquote><td>12.0%</td></blockquote></p><p></td> </tr> <tr> <td>Earnings Per Share</p><p><blockquote><tr><td>每股盈利</td></tr></blockquote></p><p></td> <td>$134.05</p><p><blockquote><td>$134.05</td></blockquote></p><p></td> <td>$0.03</p><p><blockquote><td>$0.03</td></blockquote></p><p></td> <td>-100.0%</p><p><blockquote><td>-100.0%</td></blockquote></p><p></td> </tr> <tr> <td>Revenue Growth Rate</p><p><blockquote><tr><td>收入增长率</td></tr></blockquote></p><p></td> <td>25.6%</p><p><blockquote><td>25.6%</td></blockquote></p><p></td> <td>3971.01%</p><p><blockquote><td>3971.01%</td></blockquote></p><p></td> <td>15436.03%</p><p><blockquote><td>15436.03%</td></blockquote></p><p></td> </tr> <tr> <td>(Glossary Of Terms)</p><p><blockquote><tr><td>(术语表)</td></tr></blockquote></p><p></td> </tr> </tbody> </table> <b>Commentary</b></p><p><blockquote><b>评论</b></blockquote></p><p> Cue is seeking public investment capital to further scale its commercialization operations as well as continue its R & D efforts.</p><p><blockquote>Cue正在寻求公共投资资本,以进一步扩大其商业化业务并继续其研发工作。</blockquote></p><p> The company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations</p><p><blockquote>该公司的财务数据显示,营收大幅增长,毛利润和可变毛利率强劲增长,营业利润和净利润出现波动,经营活动产生或使用的现金流高度波动</blockquote></p><p> Free cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).</p><p><blockquote>截至2021年6月30日的12个月的自由现金流是令人瞠目结舌的负值(6000万美元)。</blockquote></p><p> Sales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.</p><p><blockquote>销售和营销费用占总收入的百分比随着收入的急剧增加而波动;在最近的报告期内,其销售和营销效率高达100.5倍。</blockquote></p><p> The market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.</p><p><blockquote>新冠肺炎和相关检测试剂盒平台的市场机会很大,并且在未来几年可能会以高增长率增长,因为世界各国在最近的全球疫情之后寻求增强其检测能力。</blockquote></p><p></p><p> Goldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p><p><blockquote>高盛是首席承销商,该公司在过去12个月内牵头的IPO自IPO以来的平均回报率为39.9%。这是期内所有主要承销商的中等表现。</blockquote></p><p> The primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.</p><p><blockquote>该公司现在面临的主要风险是,它本质上是一家单一产品公司,因此其收入基础高度集中。</blockquote></p><p> As for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.</p><p><blockquote>至于估值,与部分竞争对手Bio-Rad Laboratories相比,IPO的收入倍数估值合理,尽管Cue在收入基础低得多的情况下以高得多的增长率增长,因此这种比较充其量是紧张的。</blockquote></p><p> Given Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.</p><p><blockquote>鉴于Cue的增长轨迹、盈利能力和合理的IPO估值,此次IPO值得考虑。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HLTH":"Cue Health Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104085778","content_text":"(Sept 24) Cue Health Inc. opens for trading at $19.2, up 20% from IPO price.\n\nCompany & Technology\nSan Diego, California-based Cue was founded to first develop a COVID-19 test kit and integrated information platform for processing and communication.\nManagement is headed by co-founder, Chairman and CEO Ayub Khattak, who has been with the firm since inception and holds a B.S. in mathematics from UCLA.\nThe company’s primary offerings in its Cue Integrated Care Platform:\n\nHealth monitoring system\nRader\nCartridge\nWand\nData\nDelivery apps\nEnterprise dashboard\nEcosystem integrations\n\nCue has received at least $176 million in equity investment from investors including ACME Capital, Cove Investors, Decheng Capital China Life Sciences, Madrone and NVGA I.\nCustomer/User Acquisition\nThe company pursues healthcare provider relationships through its in-house direct sales team focused on healthcare providers, large enterprises and public sector clients.\nManagement expects 2021 customer demand for its COVID-19 test kits to exceed its manufacturing capacity.\nSales and Marketing expenses as a percentage of total revenue have varied as revenues have increased sharply, as the figures below indicate:\n\n\n\nSales and Marketing\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n1.0%\n\n\n2020\n3.1%\n\n\n2019\n1.3%\n\n\n\nThe Sales and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales and Marketing spend, was 100.5x in the most recent reporting period, as shown in the table below:\n\n\n\nSales and Marketing\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n100.5\n\n\n2020\n22.9\n\n\n\nMarket & Competition\nAccording to a 2020 marketresearch reportby Grand View Research, the global market for COVID-19 detection kits was an estimated $3.28 billion in 2020 and is expected to reach $5 billion by 2027.\nThis represents a forecast CAGR of 5.05% from 2021 to 2027.\nThe main drivers for this expected growth are a strong growth in demand for testing services of all types on a global basis.\nAlso, below is a chart showing the market share of use of detection kits by end-user type:\n\n(Source)\nMajor competitive or other industry participants include:\n\nAbbott Laboratories(NYSE:ABT)\nBecton, Dickinson(NYSE:BDX)\nbioMerieux(OTCPK:BMXMF)\nBio-Rad Laboratories(NYSE:BIO)\nDanaher(NYSE:DHR)\nEllume Limited\nEverly Health\nRoche(OTCQX:RHHBY)(OTCQX:RHHBF)\nFluidigm(NASDAQ:FLDM)\nGenMark Diagnostics(NASDAQ:GNMK)\nOthers\n\nFinancial Performance\nCue’s recent financial results can be summarized as follows:\n\nSharply growing top line revenue\nIncreasing gross profit and variable gross margin\nA swing to operating profit and net income\nVariable cash flow from operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\n\n\n\nTotal Revenue\n\n\nPeriod\nTotal Revenue\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 201,922,000\n3971.0%\n\n\n2020\n$ 22,953,000\n246.4%\n\n\n2019\n$ 6,626,000\n\n\n\nGross Profit (Loss)\n\n\nPeriod\nGross Profit (Loss)\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 116,745,000\n2253.7%\n\n\n2020\n$ 8,002,000\n20.8%\n\n\n2019\n$ 6,626,000\n\n\n\nGross Margin\n\n\nPeriod\nGross Margin\n\n\nSix Mos. Ended June 30, 2021\n57.82%\n\n\n2020\n34.86%\n\n\n2019\n100.00%\n\n\n\nOperating Profit (Loss)\n\n\nPeriod\nOperating Profit (Loss)\nOperating Margin\n\n\nSix Mos. Ended June 30, 2021\n$ 79,463,000\n39.4%\n\n\n2020\n$ (45,126,000)\n-196.6%\n\n\n2019\n$ (20,767,000)\n-313.4%\n\n\n\nNet Income (Loss)\n\n\nPeriod\nNet Income (Loss)\n\n\nSix Mos. Ended June 30, 2021\n$ 32,840,000\n\n\n2020\n$ (47,352,000)\n\n\n2019\n$ (20,606,000)\n\n\n\nCash Flow From Operations\n\n\nPeriod\nCash Flow From Operations\n\n\nSix Mos. Ended June 30, 2021\n$ (37,812,000)\n\n\n2020\n$ 92,655,000\n\n\n2019\n$ (12,996,000)\n\n\n\nAs of June 30, 2021, Cue had $246.3 million in cash and $516.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($60 million).\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n\n\n\n\nMeasure [TTM]\nAmount\n\n\nMarket Capitalization at IPO\n$2,299,981,232\n\n\nEnterprise Value\n$1,874,455,232\n\n\nPrice / Sales\n10.46\n\n\nEV / Revenue\n8.52\n\n\nEV / EBITDA\n35.46\n\n\nEarnings Per Share\n$0.03\n\n\nFloat To Outstanding Shares Ratio\n8.70%\n\n\nProposed IPO Midpoint Price per Share\n$16.00\n\n\nNet Free Cash Flow\n-$59,920,000\n\n\nFree Cash Flow Yield Per Share\n-2.61%\n\n\nRevenue Growth Rate\n3971.01%\n\n\n\nAs a reference, a potential partial and imperfect public comparable to Cue would be Bio-Rad (BIO); below is a comparison of their primary valuation metrics:\n\n\n\n\nMetric\nBio-Rad (BIO)\nCue Health (HLTH)\nVariance\n\n\nPrice / Sales\n8.15\n10.46\n28.3%\n\n\nEV / Revenue\n7.82\n8.52\n9.0%\n\n\nEV / EBITDA\n31.66\n35.46\n12.0%\n\n\nEarnings Per Share\n$134.05\n$0.03\n-100.0%\n\n\nRevenue Growth Rate\n25.6%\n3971.01%\n15436.03%\n\n\n(Glossary Of Terms)\n\n\n\nCommentary\nCue is seeking public investment capital to further scale its commercialization operations as well as continue its R & D efforts.\nThe company’s financials show sharply growing top line revenue, strong growth in gross profit and variable gross margin, a swing to operating profit and net income and highly fluctuating cash flow from or use in operations\nFree cash flow for the twelve months ended June 30, 2021, was an eye-popping negative ($60 million).\nSales and Marketing expenses as a percentage of total revenue have fluctuated as revenues have increased dramatically; its Sales and Marketing efficiency rate was an extremely high 100.5x in the most recent reporting period.\nThe market opportunity for COVID-19 and related test kit platforms is large and will likely grow at a high rate of growth over the coming years as countries around the world seek to bolster their testing capabilities in the wake of the recent global pandemic.\nGoldman Sachs is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 39.9% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the firm now is that it is essentially a one-product company, so its revenue base is heavily concentrated.\nAs for valuation, compared to partial competitor Bio-Rad Laboratories, the IPO is reasonably valued on a revenue multiple, although Cue is growing at a much higher rate of growth from a much lower revenue base, so the comparison is strained at best.\nGiven Cue’s growth trajectory, profitability and reasonable IPO valuation, the IPO is worth consideration.","news_type":1,"symbols_score_info":{"HLTH":0.9}},"isVote":1,"tweetType":1,"viewCount":2751,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":882739133,"gmtCreate":1631719199322,"gmtModify":1631885315502,"author":{"id":"3581248713273658","authorId":"3581248713273658","name":"LZH97","avatar":"https://static.tigerbbs.com/0a48491665331819a9d1857c6b60743e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581248713273658","authorIdStr":"3581248713273658"},"themes":[],"htmlText":"Buy!","listText":"Buy!","text":"Buy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/882739133","repostId":"1148341685","repostType":4,"repost":{"id":"1148341685","kind":"news","pubTimestamp":1631660884,"share":"https://www.laohu8.com/m/news/1148341685?lang=zh_CN&edition=full","pubTime":"2021-09-15 07:08","market":"us","language":"en","title":"U.S. stocks close lower on worries over recovery, corporate tax hikes<blockquote>美国股市因对复苏和企业增税的担忧而收低</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1148341685","media":"Reuters","summary":"NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing","content":"<p>NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing likelihood of a corporate tax rate hike dampened investor sentiment and prompted a broad sell-off despite signs of easing inflation.</p><p><blockquote>路透纽约-华尔街周二下跌,原因是经济不确定性和企业税率上调的可能性越来越大,抑制了投资者情绪,并引发了广泛的抛售,尽管通胀有缓解的迹象。</blockquote></p><p> Optimism faded throughout the session, reversing an initial rally following the Labor Department’s consumer price index report. All three major U.S. stock indexes ended in negative territory in a reminder that September is a historically rough month for stocks.</p><p><blockquote>整个交易日乐观情绪消退,扭转了劳工部消费者价格指数报告发布后最初的涨势。美国三大股指均收于负值,提醒人们9月份对于股市来说是历史上艰难的一个月。</blockquote></p><p> So far this month the S&P 500 is down nearly 1.8% even as the benchmark index has gained over 18% since the beginning of the year.</p><p><blockquote>本月迄今为止,标普500已下跌近1.8%,尽管基准指数自年初以来已上涨超过18%。</blockquote></p><p> “There is a possibility that the market is simply ready to go through an overdue correction,” said Sam Stovall, chief investment strategist at CFRA Research in New York. “From a seasonality perspective, September tends to be the window dressing period for fund managers.”</p><p><blockquote>纽约CFRA Research首席投资策略师Sam Stovall表示:“市场有可能只是准备好经历一次迟来的调整。”“从季节性来看,9月往往是基金经理的粉饰期。”</blockquote></p><p> The advent of the highly contagious Delta COVID variant has driven an increase in bearish sentiment regarding the recovery from the global health crisis, and many now expect a substantial correction in stock markets by the end of the year.</p><p><blockquote>高度传染性的Delta COVID变种的出现导致人们对从全球健康危机中复苏的看跌情绪增加,许多人现在预计股市将在今年年底前大幅调整。</blockquote></p><p> “We’re still in a corrective mode that people have been calling for months,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “Economic data points have been missing estimates, and that has coincided with the rise in the Delta variant.”</p><p><blockquote>芝加哥Kingsview Asset Management投资组合经理保罗·诺尔特(Paul Nolte)表示:“我们仍处于人们几个月来一直呼吁的纠正模式。”“经济数据点一直低于预期,而这与德尔塔变异毒株的上升同时发生。”</blockquote></p><p> The CPI report delivered a lower-than-consensus August reading, a deceleration that supports Federal Reserve Chairman Jerome Powell’s assertion that spiking inflation is transitory and calms market fears that the central bank will begin tightening monetary policy sooner than expected.</p><p><blockquote>CPI报告公布的8月份读数低于市场普遍预期,这一减速支持了美联储主席杰罗姆·鲍威尔的说法,即通胀飙升是暂时的,并平息了市场对美联储将比预期更早开始收紧货币政策的担忧。</blockquote></p><p> U.S. Treasury yields dropped on the data, which pressured financial stocks, and investor favor pivoted back to growth at the expense of value. [US/]</p><p><blockquote>美国国债收益率因数据而下跌,这给金融股带来压力,投资者的青睐转向增长,而牺牲了价值。[美国/]</blockquote></p><p> The long expected corporate tax hikes, to 26.5% from 21% if Democrats prevail, are coming nearer to fruition with U.S. President Joe Biden’s $3.5 trillion budget package inching closer to passage.</p><p><blockquote>随着美国总统乔·拜登(Joe Biden)的3.5万亿美元预算计划逐渐接近通过,人们期待已久的公司税上调(如果民主党获胜,将从21%上调至26.5%)即将实现。</blockquote></p><p> The Dow Jones Industrial Average fell 292.06 points, or 0.84%, to 34,577.57; the S&P 500 lost 25.68 points, or 0.57%, at 4,443.05; and the Nasdaq Composite dropped 67.82 points, or 0.45%, to 15,037.76.</p><p><blockquote>道琼工业指数跌292.06点,或0.84%,报34577.57点;标普500跌25.68点,跌幅0.57%,报4,443.05点;纳斯达克综合指数下跌67.82点,跌幅0.45%,至15037.76点。</blockquote></p><p> All 11 major sectors in the S&P 500 ended the session red, with energy and financials suffering the largest percentage drops.</p><p><blockquote>标普500 11大板块全部收红,能源和金融板块跌幅最大。</blockquote></p><p> Apple Inc unveiled its iPhone 13 and added new features to its iPad and Apple Watch gadgets in its biggest product launch event of the year as the company faces increased scrutiny in the courts over its business practices. Its shares closed down 1.0% and were the heaviest drag on the S&P 500 and the Nasdaq.</p><p><blockquote>苹果公司在今年最大的产品发布会上推出了iPhone 13,并为其iPad和苹果手表设备添加了新功能,因为该公司面临着法院对其商业行为的更严格审查。其股价收盘下跌1.0%,对标普500和纳斯达克拖累最大。</blockquote></p><p> Intuit Inc gained 1.9% following the TurboTax maker’s announcement that it would acquire digital marketing company Mailchimp for $12 billion.</p><p><blockquote>TurboTax制造商Intuit Inc宣布将以120亿美元收购数字营销公司Mailchimp后,该公司股价上涨1.9%。</blockquote></p><p> CureVac slid 8.0% after the German biotechnology company canceled manufacturing deals for its experimental COVID-19 vaccine.</p><p><blockquote>德国生物技术公司CureVac取消其实验性COVID-19疫苗的生产交易后,股价下跌8.0%。</blockquote></p><p> Declining issues outnumbered advancing ones on the NYSE by a 2.25-to-1 ratio; on Nasdaq, a 2.40-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所下跌股与上涨股的比例为2.25比1;在纳斯达克,2.40比1的比率有利于下跌股。</blockquote></p><p> The S&P 500 posted two new 52-week highs and two new lows; the Nasdaq Composite recorded 50 new highs and 107 new lows.</p><p><blockquote>标普500创下两个52周新高和两个新低;纳斯达克综合指数录得50个新高和107个新低。</blockquote></p><p> Volume on U.S. exchanges was 10.07 billion shares, compared with the 9.38 billion average over the last 20 trading days.</p><p><blockquote>美国交易所成交量为100.7亿股,而过去20个交易日的平均成交量为93.8亿股。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stocks close lower on worries over recovery, corporate tax hikes<blockquote>美国股市因对复苏和企业增税的担忧而收低</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stocks close lower on worries over recovery, corporate tax hikes<blockquote>美国股市因对复苏和企业增税的担忧而收低</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-09-15 07:08</span>\n</p>\n</h4>\n</header>\n<article>\n<p>NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing likelihood of a corporate tax rate hike dampened investor sentiment and prompted a broad sell-off despite signs of easing inflation.</p><p><blockquote>路透纽约-华尔街周二下跌,原因是经济不确定性和企业税率上调的可能性越来越大,抑制了投资者情绪,并引发了广泛的抛售,尽管通胀有缓解的迹象。</blockquote></p><p> Optimism faded throughout the session, reversing an initial rally following the Labor Department’s consumer price index report. All three major U.S. stock indexes ended in negative territory in a reminder that September is a historically rough month for stocks.</p><p><blockquote>整个交易日乐观情绪消退,扭转了劳工部消费者价格指数报告发布后最初的涨势。美国三大股指均收于负值,提醒人们9月份对于股市来说是历史上艰难的一个月。</blockquote></p><p> So far this month the S&P 500 is down nearly 1.8% even as the benchmark index has gained over 18% since the beginning of the year.</p><p><blockquote>本月迄今为止,标普500已下跌近1.8%,尽管基准指数自年初以来已上涨超过18%。</blockquote></p><p> “There is a possibility that the market is simply ready to go through an overdue correction,” said Sam Stovall, chief investment strategist at CFRA Research in New York. “From a seasonality perspective, September tends to be the window dressing period for fund managers.”</p><p><blockquote>纽约CFRA Research首席投资策略师Sam Stovall表示:“市场有可能只是准备好经历一次迟来的调整。”“从季节性来看,9月往往是基金经理的粉饰期。”</blockquote></p><p> The advent of the highly contagious Delta COVID variant has driven an increase in bearish sentiment regarding the recovery from the global health crisis, and many now expect a substantial correction in stock markets by the end of the year.</p><p><blockquote>高度传染性的Delta COVID变种的出现导致人们对从全球健康危机中复苏的看跌情绪增加,许多人现在预计股市将在今年年底前大幅调整。</blockquote></p><p> “We’re still in a corrective mode that people have been calling for months,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “Economic data points have been missing estimates, and that has coincided with the rise in the Delta variant.”</p><p><blockquote>芝加哥Kingsview Asset Management投资组合经理保罗·诺尔特(Paul Nolte)表示:“我们仍处于人们几个月来一直呼吁的纠正模式。”“经济数据点一直低于预期,而这与德尔塔变异毒株的上升同时发生。”</blockquote></p><p> The CPI report delivered a lower-than-consensus August reading, a deceleration that supports Federal Reserve Chairman Jerome Powell’s assertion that spiking inflation is transitory and calms market fears that the central bank will begin tightening monetary policy sooner than expected.</p><p><blockquote>CPI报告公布的8月份读数低于市场普遍预期,这一减速支持了美联储主席杰罗姆·鲍威尔的说法,即通胀飙升是暂时的,并平息了市场对美联储将比预期更早开始收紧货币政策的担忧。</blockquote></p><p> U.S. Treasury yields dropped on the data, which pressured financial stocks, and investor favor pivoted back to growth at the expense of value. [US/]</p><p><blockquote>美国国债收益率因数据而下跌,这给金融股带来压力,投资者的青睐转向增长,而牺牲了价值。[美国/]</blockquote></p><p> The long expected corporate tax hikes, to 26.5% from 21% if Democrats prevail, are coming nearer to fruition with U.S. President Joe Biden’s $3.5 trillion budget package inching closer to passage.</p><p><blockquote>随着美国总统乔·拜登(Joe Biden)的3.5万亿美元预算计划逐渐接近通过,人们期待已久的公司税上调(如果民主党获胜,将从21%上调至26.5%)即将实现。</blockquote></p><p> The Dow Jones Industrial Average fell 292.06 points, or 0.84%, to 34,577.57; the S&P 500 lost 25.68 points, or 0.57%, at 4,443.05; and the Nasdaq Composite dropped 67.82 points, or 0.45%, to 15,037.76.</p><p><blockquote>道琼工业指数跌292.06点,或0.84%,报34577.57点;标普500跌25.68点,跌幅0.57%,报4,443.05点;纳斯达克综合指数下跌67.82点,跌幅0.45%,至15037.76点。</blockquote></p><p> All 11 major sectors in the S&P 500 ended the session red, with energy and financials suffering the largest percentage drops.</p><p><blockquote>标普500 11大板块全部收红,能源和金融板块跌幅最大。</blockquote></p><p> Apple Inc unveiled its iPhone 13 and added new features to its iPad and Apple Watch gadgets in its biggest product launch event of the year as the company faces increased scrutiny in the courts over its business practices. Its shares closed down 1.0% and were the heaviest drag on the S&P 500 and the Nasdaq.</p><p><blockquote>苹果公司在今年最大的产品发布会上推出了iPhone 13,并为其iPad和苹果手表设备添加了新功能,因为该公司面临着法院对其商业行为的更严格审查。其股价收盘下跌1.0%,对标普500和纳斯达克拖累最大。</blockquote></p><p> Intuit Inc gained 1.9% following the TurboTax maker’s announcement that it would acquire digital marketing company Mailchimp for $12 billion.</p><p><blockquote>TurboTax制造商Intuit Inc宣布将以120亿美元收购数字营销公司Mailchimp后,该公司股价上涨1.9%。</blockquote></p><p> CureVac slid 8.0% after the German biotechnology company canceled manufacturing deals for its experimental COVID-19 vaccine.</p><p><blockquote>德国生物技术公司CureVac取消其实验性COVID-19疫苗的生产交易后,股价下跌8.0%。</blockquote></p><p> Declining issues outnumbered advancing ones on the NYSE by a 2.25-to-1 ratio; on Nasdaq, a 2.40-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所下跌股与上涨股的比例为2.25比1;在纳斯达克,2.40比1的比率有利于下跌股。</blockquote></p><p> The S&P 500 posted two new 52-week highs and two new lows; the Nasdaq Composite recorded 50 new highs and 107 new lows.</p><p><blockquote>标普500创下两个52周新高和两个新低;纳斯达克综合指数录得50个新高和107个新低。</blockquote></p><p> Volume on U.S. exchanges was 10.07 billion shares, compared with the 9.38 billion average over the last 20 trading days.</p><p><blockquote>美国交易所成交量为100.7亿股,而过去20个交易日的平均成交量为93.8亿股。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.reuters.com/article/usa-stocks/u-s-stocks-close-lower-on-worries-over-recovery-corporate-tax-hikes-idUSKBN2GA0W9\">Reuters</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.reuters.com/article/usa-stocks/u-s-stocks-close-lower-on-worries-over-recovery-corporate-tax-hikes-idUSKBN2GA0W9","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148341685","content_text":"NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing likelihood of a corporate tax rate hike dampened investor sentiment and prompted a broad sell-off despite signs of easing inflation.\nOptimism faded throughout the session, reversing an initial rally following the Labor Department’s consumer price index report. All three major U.S. stock indexes ended in negative territory in a reminder that September is a historically rough month for stocks.\nSo far this month the S&P 500 is down nearly 1.8% even as the benchmark index has gained over 18% since the beginning of the year.\n“There is a possibility that the market is simply ready to go through an overdue correction,” said Sam Stovall, chief investment strategist at CFRA Research in New York. “From a seasonality perspective, September tends to be the window dressing period for fund managers.”\nThe advent of the highly contagious Delta COVID variant has driven an increase in bearish sentiment regarding the recovery from the global health crisis, and many now expect a substantial correction in stock markets by the end of the year.\n“We’re still in a corrective mode that people have been calling for months,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “Economic data points have been missing estimates, and that has coincided with the rise in the Delta variant.”\nThe CPI report delivered a lower-than-consensus August reading, a deceleration that supports Federal Reserve Chairman Jerome Powell’s assertion that spiking inflation is transitory and calms market fears that the central bank will begin tightening monetary policy sooner than expected.\nU.S. Treasury yields dropped on the data, which pressured financial stocks, and investor favor pivoted back to growth at the expense of value. [US/]\nThe long expected corporate tax hikes, to 26.5% from 21% if Democrats prevail, are coming nearer to fruition with U.S. President Joe Biden’s $3.5 trillion budget package inching closer to passage.\nThe Dow Jones Industrial Average fell 292.06 points, or 0.84%, to 34,577.57; the S&P 500 lost 25.68 points, or 0.57%, at 4,443.05; and the Nasdaq Composite dropped 67.82 points, or 0.45%, to 15,037.76.\nAll 11 major sectors in the S&P 500 ended the session red, with energy and financials suffering the largest percentage drops.\nApple Inc unveiled its iPhone 13 and added new features to its iPad and Apple Watch gadgets in its biggest product launch event of the year as the company faces increased scrutiny in the courts over its business practices. Its shares closed down 1.0% and were the heaviest drag on the S&P 500 and the Nasdaq.\nIntuit Inc gained 1.9% following the TurboTax maker’s announcement that it would acquire digital marketing company Mailchimp for $12 billion.\nCureVac slid 8.0% after the German biotechnology company canceled manufacturing deals for its experimental COVID-19 vaccine.\nDeclining issues outnumbered advancing ones on the NYSE by a 2.25-to-1 ratio; on Nasdaq, a 2.40-to-1 ratio favored decliners.\nThe S&P 500 posted two new 52-week highs and two new lows; the Nasdaq Composite recorded 50 new highs and 107 new lows.\nVolume on U.S. exchanges was 10.07 billion shares, compared with the 9.38 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{".IXIC":0.9,".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":817666038,"gmtCreate":1630942284624,"gmtModify":1631885315517,"author":{"id":"3581248713273658","authorId":"3581248713273658","name":"LZH97","avatar":"https://static.tigerbbs.com/0a48491665331819a9d1857c6b60743e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581248713273658","authorIdStr":"3581248713273658"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/817666038","repostId":"1121396906","repostType":4,"isVote":1,"tweetType":1,"viewCount":3181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814904982,"gmtCreate":1630736167546,"gmtModify":1631885315529,"author":{"id":"3581248713273658","authorId":"3581248713273658","name":"LZH97","avatar":"https://static.tigerbbs.com/0a48491665331819a9d1857c6b60743e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581248713273658","authorIdStr":"3581248713273658"},"themes":[],"htmlText":"Like and shareeee","listText":"Like and shareeee","text":"Like and shareeee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/814904982","repostId":"1196145266","repostType":4,"isVote":1,"tweetType":1,"viewCount":2531,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894642281,"gmtCreate":1628824653543,"gmtModify":1631885315567,"author":{"id":"3581248713273658","authorId":"3581248713273658","name":"LZH97","avatar":"https://static.tigerbbs.com/0a48491665331819a9d1857c6b60743e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581248713273658","authorIdStr":"3581248713273658"},"themes":[],"htmlText":"Liked and sharee","listText":"Liked and sharee","text":"Liked and sharee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/894642281","repostId":"1188620903","repostType":4,"isVote":1,"tweetType":1,"viewCount":1461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891774812,"gmtCreate":1628437304836,"gmtModify":1631885315575,"author":{"id":"3581248713273658","authorId":"3581248713273658","name":"LZH97","avatar":"https://static.tigerbbs.com/0a48491665331819a9d1857c6b60743e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581248713273658","authorIdStr":"3581248713273658"},"themes":[],"htmlText":"Like and share","listText":"Like and share","text":"Like and share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/891774812","repostId":"2157901414","repostType":4,"isVote":1,"tweetType":1,"viewCount":1551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}